Skip to main navigation Skip to search Skip to main content

Crystallization and preliminary crystallographic analysis of a novel cytochrome P450 from Mycobacterium tuberculosis

  • Christopher G. Mowat
  • , David Leys
  • , Kirsty J. McLean
  • , Stuart L. Rivers
  • , Alison Richmond
  • , Andrew W. Munro
  • , Miguel Ortiz Lombardia
  • , Pedro M. Alzari
  • , Graeme A. Reid
  • , Stephen K. Chapman
  • , Malcolm D. Walkinshaw

    Research output: Contribution to journalArticlepeer-review

    Abstract

    The product of the Rv2276 gene of Mycobacterium tuberculosis is a cytochrome P450 (P450 MT2, CYP121) which has been shown to bind tightly to a range of azole-based antifungal drugs (e.g. miconazole, clotrimazole). These drugs are potent inhibitors of mycobacterial growth, suggesting that P450 MT2 (CYP121) may be a potential drug target. The enzyme has been overexpressed in Escherichia coli and crystallized by the hanging-drop method. Crystals of P450 MT2 (CYP121) belong to the hexagonal space group P6122 or P6522, with unit-cell parameters a = b = 78.3, c = 265.6 Å. Native data have been collected to 1.6 Å resolution and Hg-derivative data to 2.5 Å resolution using a synchrotron-radiation source.
    Original languageEnglish
    Pages (from-to)704-705
    Number of pages1
    JournalActa Crystallographica Section D: Biological Crystallography
    Volume58
    Issue number4
    DOIs
    Publication statusPublished - 2002

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Fingerprint

    Dive into the research topics of 'Crystallization and preliminary crystallographic analysis of a novel cytochrome P450 from Mycobacterium tuberculosis'. Together they form a unique fingerprint.

    Cite this